Invitrogen™ p14ARF Polyclonal Antibody

Rabbit Polyclonal Antibody

Supplier:  Invitrogen™ PA146021

Catalog No. PA146021

Description

By Western blot, PA1-46021 is specific for the ~16 kDa CDKN2A protein (CDKN2A tends to run slightly higher than the theoretical MW of 14 kDa). Additional non-specific bands may be seen at ~25 and 47 kDa. Suggested positive control: BT549 cells or HeLa whole cell extract, antigen standard for CDKN2A (transient overexpression lysate).

The INK4a locus on chromosome 9p21 is frequently affected in human tumors. It encodes two structurally distinct tumor suppressor proteins, p16INK4a and the alternative reading frame protein, ARF (p14ARF in human and P19ARF in mouse). These two proteins interact with the upstream proteins: retinoblastoma protein and p53 tumor suppressors, respectively. Each of these proteins has a role in the senescence of primary cells, activates pathways for cell cycle control and tumor suppression. The p14ARF (or P19ARF in mouse) proteins can induce both G1 and G2 phase arrest in a manner that depends on functional p53. The mouse and human ARF proteins have different functions in tumor suppression; this distinction may contribute to the different levels of tumor proneness of these species.

Specifications

• Antigen: p14ARF
• Classification: Polyclonal
• Conjugate: Unconjugated
• Gene: CDKN2A
• Gene Alias: Alternative reading frame; ARF; ARF-INK4a; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; CDKN2A; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; p14 p16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; P16INK4A; P16-INK4A; P19; P19 TP16; p19>ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
• Host Species: Rabbit
• Purification Method: Antigen Affinity Chromatography
• Regulatory Status: RUO
• Gene ID (Entrez): 1029
• Content And Storage: -20°C or -80°C if preferred
• Form: Liquid

• Applications: Western Blot
• Concentration: 2.5 mg/mL
• Formulation: TBS with 0.05% sodium azide
• Gene Accession No.: P42771, Q8N726
• Gene Symbols: CDKN2A
• Immunogen: A synthetic peptide made to a region within residues 100-173 of the human CDKN2A protein.
• Quantity: 100 μL
• Primary or Secondary: Primary
• Target Species: Human
• Product Type: Antibody
• Isotype: IgG